Trial · NCT03038672
Adverse events555
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 555
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Group I (Nivolumab) | 8 | 27 | 8 |
| other | Anemia | Blood and lymphatic system disorders | Group II (Varlilumab, Nivolumab) | 13 | 27 | 18 |
| other | Anemia | Blood and lymphatic system disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 1 | 7 | 1 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Group I (Nivolumab) | 3 | 27 | 3 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Group II (Varlilumab, Nivolumab) | 5 | 27 | 5 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 1 | 7 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group I (Nivolumab) | 0 | 27 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group II (Varlilumab, Nivolumab) | 2 | 27 | 2 |
| other | Leukocytosis | Blood and lymphatic system disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 0 | 7 | 0 |
| other | Atrioventricular block complete | Cardiac disorders | Group I (Nivolumab) | 1 | 27 | 1 |
| other | Atrioventricular block complete | Cardiac disorders | Group II (Varlilumab, Nivolumab) | 0 | 27 | 0 |
| other | Atrioventricular block complete | Cardiac disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 0 | 7 | 0 |
| other | Palpitations | Cardiac disorders | Group I (Nivolumab) | 0 | 27 | 0 |
| other | Palpitations | Cardiac disorders | Group II (Varlilumab, Nivolumab) | 0 | 27 | 0 |
| other | Palpitations | Cardiac disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 1 | 7 | 1 |
| other | Pericardial effusion | Cardiac disorders | Group I (Nivolumab) | 0 | 27 | 0 |
| other | Pericardial effusion | Cardiac disorders | Group II (Varlilumab, Nivolumab) | 1 | 27 | 1 |
| other | Pericardial effusion | Cardiac disorders | Cross Over to Group II Treatment (Varlilumab, Nivolumab) | 0 | 7 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Group I (Nivolumab) | 1 | 27 | 1 |
| other | Sinus bradycardia | Cardiac disorders | Group II (Varlilumab, Nivolumab) | 0 | 27 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03038672/events